CL2009002183A1 - Uso de una composicion topica que comprende 2.5% de imiquimod y un vehiculo farmaceuticamente aceptable para preparar un medicamento util para tratar queratosisi actinica; composicion topica. - Google Patents

Uso de una composicion topica que comprende 2.5% de imiquimod y un vehiculo farmaceuticamente aceptable para preparar un medicamento util para tratar queratosisi actinica; composicion topica.

Info

Publication number
CL2009002183A1
CL2009002183A1 CL2009002183A CL2009002183A CL2009002183A1 CL 2009002183 A1 CL2009002183 A1 CL 2009002183A1 CL 2009002183 A CL2009002183 A CL 2009002183A CL 2009002183 A CL2009002183 A CL 2009002183A CL 2009002183 A1 CL2009002183 A1 CL 2009002183A1
Authority
CL
Chile
Prior art keywords
topical composition
imiquimod
prepare
actinic keratosis
pharmaceutically acceptable
Prior art date
Application number
CL2009002183A
Other languages
English (en)
Inventor
T Nordsiek Michael
F Levy Sharon
H Lee James
H Kulp James
S Balaji Kodumudi
Meng Tze-Chiang
J Wu Jason
S Baham Valyn
Rob
Original Assignee
Medicis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42316709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009002183(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medicis Pharmaceutical Corp filed Critical Medicis Pharmaceutical Corp
Publication of CL2009002183A1 publication Critical patent/CL2009002183A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Abstract

Método para tratar a un sujeto la queratosis actínica que comprende aplicar una cantidad efectiva de imiquimod a un área de tratamiento una vez al día hasta por 6 semanas para lograr una curación por lo menos parcial de las lesiones; formulación de imiquimod que comprende una concentración más baja de la dosis de imiquimod.
CL2009002183A 2008-12-19 2009-12-17 Uso de una composicion topica que comprende 2.5% de imiquimod y un vehiculo farmaceuticamente aceptable para preparar un medicamento util para tratar queratosisi actinica; composicion topica. CL2009002183A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13953608P 2008-12-19 2008-12-19
US14473109P 2009-01-14 2009-01-14
US20514509P 2009-01-15 2009-01-15

Publications (1)

Publication Number Publication Date
CL2009002183A1 true CL2009002183A1 (es) 2011-01-07

Family

ID=42316709

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009002183A CL2009002183A1 (es) 2008-12-19 2009-12-17 Uso de una composicion topica que comprende 2.5% de imiquimod y un vehiculo farmaceuticamente aceptable para preparar un medicamento util para tratar queratosisi actinica; composicion topica.

Country Status (27)

Country Link
US (13) US20110021555A1 (es)
EP (1) EP2378876B1 (es)
AR (1) AR074802A1 (es)
AU (1) AU2009335943A1 (es)
BR (1) BRPI0923164A2 (es)
CL (1) CL2009002183A1 (es)
CO (1) CO6400171A2 (es)
CR (1) CR20110338A (es)
CY (1) CY1121485T1 (es)
DK (1) DK2378876T3 (es)
DO (1) DOP2011000195A (es)
EA (1) EA201100984A1 (es)
ES (1) ES2720149T3 (es)
GE (1) GEP20146198B (es)
HR (1) HRP20190306T1 (es)
HU (1) HUE041944T2 (es)
IL (2) IL213628A (es)
LT (1) LT2378876T (es)
MX (2) MX346455B (es)
PA (1) PA8855101A1 (es)
PE (2) PE20100469A1 (es)
PL (1) PL2378876T3 (es)
PT (1) PT2378876T (es)
RS (1) RS58566B1 (es)
SI (1) SI2378876T1 (es)
TW (1) TWI442923B (es)
WO (1) WO2010080345A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
US20110030104A1 (en) 2008-08-29 2011-02-03 Los Alamos National Security, Llc Nucleic acids encoding plant glutamine phenylpyruvate transaminase (GPT) and uses thereof
US20110030089A1 (en) 2008-08-29 2011-02-03 Los Alamos National Security, Llc Transgenic plants with enhanced growth characteristics
SI2378876T1 (sl) * 2008-12-19 2019-05-31 Medicis Pharmaceutical Corporation Formulacije z nižjo dozirno jakostjo imikvimoda in kratki odmerni režimi za zdravljenje aktinične keratoze
EA025993B1 (ru) 2009-07-13 2017-02-28 Медисис Фармасьютикал Корпорейшн Композиции с более низким содержанием имиквимода и короткие режимы дозирования для лечения остроконечных и перианальных бородавок
DK2584900T3 (en) 2010-06-25 2019-04-01 Medicis Pharmaceutical Corp Combination therapy with cryosurgery and low-dose imiquimod for the treatment of actinic keratosis
US9072876B2 (en) 2010-08-05 2015-07-07 Medicis Pharmaceutical Corporation Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
WO2013040447A2 (en) * 2011-09-14 2013-03-21 Medicis Pharmaceutical Corporation Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
DK2785336T3 (da) * 2011-11-30 2016-01-11 Merz Pharma Gmbh & Co Kgaa Anvendelse af pegylerede alkoholer til behandling af aktinisk keratose
CA2871490C (en) 2012-04-27 2022-10-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cpg oligonucleotides co-formulated with an antibiotic to accelerate wound healing
SG10201907501QA (en) 2013-08-30 2019-10-30 Immunogen Inc Antibodies and assays for detection of folate receptor 1
US9711014B2 (en) 2013-09-06 2017-07-18 Immersion Corporation Systems and methods for generating haptic effects associated with transitions in audio signals
US9576445B2 (en) 2013-09-06 2017-02-21 Immersion Corp. Systems and methods for generating haptic effects associated with an envelope in audio signals
US9619980B2 (en) 2013-09-06 2017-04-11 Immersion Corporation Systems and methods for generating haptic effects associated with audio signals
MY174670A (en) * 2013-10-08 2020-05-06 Immunogen Inc Anti-folr1 immunoconjugate dosing regimens
UA121222C2 (uk) * 2014-09-10 2020-04-27 Вашингтон Юніверсіті Композиції та способи для лікування передракових уражень шкіри
CN108601828B (zh) 2015-09-17 2023-04-28 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合
WO2018165647A1 (en) * 2017-03-10 2018-09-13 Athenex, Inc. Methods of treating and/or preventing actinic keratosis
WO2020180424A1 (en) 2019-03-04 2020-09-10 Iocurrents, Inc. Data compression and communication using machine learning

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT610737A (es) 1955-11-18 1900-01-01
US4722941A (en) * 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4411893A (en) * 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4751087A (en) 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
US4746515A (en) 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
SE9601528D0 (sv) 1996-04-23 1996-04-23 Pharmacia Ab Transdermally administered dextromethorphan as antitissue agent
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US20030007939A1 (en) * 1998-07-31 2003-01-09 Howard Murad Pharmaceutical compositions and methods for managing dermatological conditions
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
SK287112B6 (sk) 1999-01-08 2009-12-07 3M Innovative Properties Company Použitie zlúčeniny modifikujúcej imunitnú odpoveď pri liečení cervikálnej dysplázie
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
US6894060B2 (en) * 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) * 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
JP2005519849A (ja) 2001-06-15 2005-07-07 スリーエム イノベイティブ プロパティズ カンパニー 歯周病の治療用免疫応答調節剤
PL210514B1 (pl) * 2001-11-29 2012-01-31 3M Innovative Properties Co Preparat farmaceutyczny zawierający modyfikator odpowiedzi immunologicznej
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7893083B2 (en) * 2003-01-06 2011-02-22 Eugene Mandrea Method of treating genital herpes
CA2518082C (en) * 2003-03-13 2013-02-12 3M Innovative Properties Company Methods for diagnosing skin lesions
NZ567227A (en) * 2003-03-13 2010-01-29 3M Innovative Properties Co Methods of improving skin quality through topical application of an immune response modifier such as imiquimod
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US20090232755A1 (en) * 2003-07-28 2009-09-17 Leslie Baumann Combination therapies for treating photodamaged skin
US7521459B2 (en) 2003-07-28 2009-04-21 Metabeauty Inc. Method for treating damaged skin
CA2536578A1 (en) 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions
WO2005066123A1 (en) 2003-12-31 2005-07-21 Taigen Biotechnology Protease inhibitors
US20070134273A1 (en) * 2004-02-10 2007-06-14 Francois Romagne Composition and method for the treatment of carcinoma
US20080125485A1 (en) * 2004-02-17 2008-05-29 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
AU2005244260B2 (en) * 2004-04-09 2010-08-05 3M Innovative Properties Company Methods, compositions, and preparations for delivery of immune response modifiers
US20070196452A1 (en) 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
CN1286529C (zh) 2004-06-11 2006-11-29 华中科技大学 具有皮肤靶向性的药物组合物及其制备方法和用途
US20060062755A1 (en) * 2004-09-21 2006-03-23 Woodward John R Method of cancer screening; method of cancer treatment; and method of diabetes treatment
DE102004049223A1 (de) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
US20060105028A1 (en) * 2004-11-12 2006-05-18 Jie Zhang Systems and methods for treating warts
US8080560B2 (en) 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US20070049518A1 (en) * 2005-08-31 2007-03-01 Chandler Stephen R Novel method of treatment of inflammatory skin conditions
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
WO2007032009A2 (en) * 2005-09-15 2007-03-22 Biomas Ltd. Use of tellurium compounds for treatment of basal cell carcinoma and/or actinic keratosis
US20070081962A1 (en) 2005-10-06 2007-04-12 Amit Munshi Novel delivery of immune response modifiers for removal of chronic tattoos
GB0524962D0 (en) * 2005-12-07 2006-01-18 Pharmakodex Ltd Topical pharmaceutical compositions
US20070264317A1 (en) 2006-05-15 2007-11-15 Perrigo Israel Pharmaceuticals Ltd. Imiquimod cream formulation
CA2659095C (en) * 2006-07-14 2015-04-28 Stiefel Research Australia Pty Ltd Fatty acid pharmaceutical foam
US20100092401A1 (en) 2006-07-18 2010-04-15 Graceway Pharmaceuticals, Llc Immune response modifier formulations
AU2007279376B2 (en) 2006-07-31 2012-09-06 Wirra Ip Pty Ltd Immune response modifier compositions and methods
TW200819435A (en) * 2006-09-15 2008-05-01 Celgene Corp N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same
HUE035308T2 (en) * 2006-09-26 2018-05-02 Celgene Corp 5-substituted quinazoline derivatives as anticancer agents
JP5389668B2 (ja) * 2007-01-31 2014-01-15 チョンシー ユー 皮膚浸透率の非常に高い１Ｈ−イミダゾ［４，５−ｃ］キノリン−４−アミン及び関連化合物の正に荷電した水溶性プロドラッグ
US20090018155A1 (en) * 2007-02-08 2009-01-15 Gregory Jefferson J Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
WO2008118881A1 (en) 2007-03-23 2008-10-02 Graceway Pharmaceuticals, Llc Method and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
WO2008118765A1 (en) 2007-03-23 2008-10-02 Graceway Pharmaceuticals, Llc Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
WO2008140713A1 (en) 2007-05-08 2008-11-20 The Brigham And Women's Hospital, Inc Methods and products for treating proliferative disorders
US8636982B2 (en) * 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
GB0715428D0 (en) 2007-08-08 2007-09-19 Imp Innovations Ltd Compositions and uses thereof
US20090130029A1 (en) * 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
US9439857B2 (en) * 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
BRPI0907191A2 (pt) 2008-01-15 2015-07-14 Dow Pharmaceutical Sciences Solução, método para preparar uma solução, método para aumentar a penetração cutânea de imiquimod ou um análogo do mesmo
MX2010008468A (es) 2008-01-31 2010-08-30 Curevac Gmbh Acidos nucleicos de la formula (i) (nug1xmgnnv)a y derivados de los mismos como un agente/adyuvante inmunoestimulante.
US20090246156A1 (en) * 2008-03-31 2009-10-01 Audrey Kunin Anti-acne sunscreen composition
WO2009145841A1 (en) * 2008-04-03 2009-12-03 Cognate 3, Llc Compositions and methods for immunotherapy
US9393295B2 (en) 2008-04-28 2016-07-19 Novartis Ag Nanoparticles for use in pharmaceutical compositions
US20110077297A1 (en) 2008-05-30 2011-03-31 Novelix Pharmaceuticals, Inc. Compositions and methods for treatment of inflammation and hyperkeratotic lesions
CN102076333A (zh) 2008-06-26 2011-05-25 安特里奥公司 真皮递送
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
KR20110090892A (ko) 2008-10-31 2011-08-10 모베르그 데르마 아베 두 개 이상의 침투 증강제의 조합으로 구성되는 국소 조성물
SI2378876T1 (sl) * 2008-12-19 2019-05-31 Medicis Pharmaceutical Corporation Formulacije z nižjo dozirno jakostjo imikvimoda in kratki odmerni režimi za zdravljenje aktinične keratoze
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EA025993B1 (ru) 2009-07-13 2017-02-28 Медисис Фармасьютикал Корпорейшн Композиции с более низким содержанием имиквимода и короткие режимы дозирования для лечения остроконечных и перианальных бородавок
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US9072876B2 (en) * 2010-08-05 2015-07-07 Medicis Pharmaceutical Corporation Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
WO2013040447A2 (en) * 2011-09-14 2013-03-21 Medicis Pharmaceutical Corporation Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis

Also Published As

Publication number Publication date
US11318130B2 (en) 2022-05-03
PE20100469A1 (es) 2010-07-31
HUE041944T2 (hu) 2019-06-28
CR20110338A (es) 2011-11-10
US20110263633A1 (en) 2011-10-27
US8299109B2 (en) 2012-10-30
LT2378876T (lt) 2019-04-25
CO6400171A2 (es) 2012-03-15
BRPI0923164A2 (pt) 2016-01-26
US20110257217A1 (en) 2011-10-20
TW201040173A (en) 2010-11-16
US20200276182A1 (en) 2020-09-03
AR074802A1 (es) 2011-02-16
US20110263637A1 (en) 2011-10-27
DK2378876T3 (en) 2019-03-11
TWI442923B (zh) 2014-07-01
US20110257218A1 (en) 2011-10-20
IL255163A0 (en) 2017-12-31
US10238644B2 (en) 2019-03-26
EP2378876B1 (en) 2018-11-14
US20110263634A1 (en) 2011-10-27
CY1121485T1 (el) 2020-05-29
EA201100984A1 (ru) 2012-01-30
US8236816B2 (en) 2012-08-07
IL213628A0 (en) 2011-07-31
MX2011001555A (es) 2011-04-14
US20110257219A1 (en) 2011-10-20
RS58566B1 (sr) 2019-05-31
US9370509B2 (en) 2016-06-21
SI2378876T1 (sl) 2019-05-31
IL255163B (en) 2019-01-31
US20110263635A1 (en) 2011-10-27
US20110263636A1 (en) 2011-10-27
US20110021555A1 (en) 2011-01-27
AU2009335943A1 (en) 2013-10-24
US20130210855A1 (en) 2013-08-15
EP2378876A1 (en) 2011-10-26
US8222270B2 (en) 2012-07-17
GEP20146198B (en) 2014-11-25
PL2378876T3 (pl) 2019-06-28
ES2720149T3 (es) 2019-07-18
DOP2011000195A (es) 2011-12-15
PE20142367A1 (es) 2015-01-10
PA8855101A1 (es) 2010-07-27
US20110257216A1 (en) 2011-10-20
MX346455B (es) 2017-03-21
WO2010080345A1 (en) 2010-07-15
US20160303111A1 (en) 2016-10-20
EP2378876A4 (en) 2012-12-05
HRP20190306T1 (hr) 2019-05-03
IL213628A (en) 2017-11-30
PT2378876T (pt) 2019-03-01

Similar Documents

Publication Publication Date Title
CL2009002183A1 (es) Uso de una composicion topica que comprende 2.5% de imiquimod y un vehiculo farmaceuticamente aceptable para preparar un medicamento util para tratar queratosisi actinica; composicion topica.
ECSP24034690A (es) Formulación tópica para un inhibidor de jak
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
CO6761350A2 (es) Derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituidos con aminoalcoholes que son de utilidad para tratar trastornos hiperproliferativos y enfermedades asociadas a la angiogenesis
CL2011002858A1 (es) Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor.
BRPI0508540A (pt) composto, composição farmacêutica, e, uso de um composto
BR112014015482A2 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
PE20170302A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
AR095197A1 (es) Combinación de un inhibidor de egfr t790m y un inhibidor de egfr para el tratamiento del cáncer pulmonar de células no pequeñas
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
BR112013007343A2 (pt) métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica
BR112013017953A2 (pt) Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.
AR063782A1 (es) Parche y metodo transdermico para emesis
GB2523707A (en) Novel pharmaceutical formulations and their use in the treatment of periodontal disease
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
EA201270747A1 (ru) Композиции и способы для профилактики и лечения ран
EA201390345A1 (ru) Терапевтическое болеутоляющее средство
DOP2013000004A (es) Agentes terapeuticos 976
BR112013025410A2 (pt) tratamento terapêutico
AR081024A1 (es) Asociacion de los inhibidores de la xantina oxidasa y la metformina y su uso
AR108793A1 (es) Composiciones que comprenden timolol y un agente antiinflamatorio
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico
AR045177A1 (es) Uso de un compuesto tazaroteno para preparar una composicion farmaceutica de utilidad para tratar acne noduloquistico severo o grave
DE602005019533D1 (de) Pharmazeutische Zusammensetzung enthaltend in Assoziation Ubidecarenon, Dexpanthenol und Chlorhexidine oder eines seiner pharmazeutischen unbedenklichen Salze zur Anwendung auf der Haut